UK markets close in 7 hours 26 minutes
  • FTSE 100

    7,181.82
    +35.14 (+0.49%)
     
  • FTSE 250

    22,818.76
    +74.25 (+0.33%)
     
  • AIM

    1,250.57
    -0.39 (-0.03%)
     
  • GBP/EUR

    1.1622
    -0.0014 (-0.12%)
     
  • GBP/USD

    1.4118
    +0.0010 (+0.07%)
     
  • BTC-GBP

    28,581.68
    +80.80 (+0.28%)
     
  • CMC Crypto 200

    1,013.37
    +44.53 (+4.60%)
     
  • S&P 500

    4,255.15
    +7.71 (+0.18%)
     
  • DOW

    34,393.75
    -85.85 (-0.25%)
     
  • CRUDE OIL

    71.24
    +0.36 (+0.51%)
     
  • GOLD FUTURES

    1,868.70
    +2.80 (+0.15%)
     
  • NIKKEI 225

    29,441.30
    +279.50 (+0.96%)
     
  • HANG SENG

    28,655.14
    -186.99 (-0.65%)
     
  • DAX

    15,786.97
    +113.33 (+0.72%)
     
  • CAC 40

    6,647.67
    +31.32 (+0.47%)
     

Adamas Announces New Employment Inducement Grant

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

EMERYVILLE, Calif., Jun 11, 2021--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005447/en/

Contacts

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
peter.vozzo@westwicke.com